Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_2:p1
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 2 (pt 1/13)
Character Range: 17473198–17476546

2  Variation rules

         The following table sets out variation rules for variations codes, for the purposes of sections 15 and 16.

Variation Code  Listed Drug                Variation Rules
V4077           Granisetron                Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.
V4118           Granisetron                Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.
                Ondansetron
V4139           Granisetron                Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.
V5618           Ondansetron                Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.
V5721           Ondansetron                Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.
V5743           Ondansetron                Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.
V5778           Ondansetron                Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle.
V7273           Icatibant                  Increased maximum quantities will be limited to 12 injections per authority prescription.
V7274           Icatibant                  Increased maximum quantities will be limited to 12 injections per authority prescription.
V7433           Axitinib                   Prescribers may request an increased maximum quantity sufficient to provide up to one month's supply for patients who require dose adjustment.
V8588           Axitinib                   Prescribers may request an increased maximum quantity sufficient to provide up to one month's supply for patients who require dose adjustment.
V9041           Pegvisomant                No increase in the maximum quantity or number of units may be authorised for the loading dose.
V9919           Sodium phenylbutyrate      An increase in the maximum quantity will be authorised to provide for up to one month's supply at a dose of up to 600 mg/kg/day in patients weighing less than 20 kg and up to 13 g/m2/day in patients weighing more than 20 kg.
V9993           Sodium phenylbutyrate      An increase in the maximum quantity will be authorised to provide for up to one month's supply at a dose of up to 600 mg/kg/day in patients weighing less than 20 kg and up to 13 g/m2/day in patients weighing more than 20 kg.
V10748          Buprenorphine              Authorities for increased maximum quantities and/or repeats must only be considered for chronic severe disabling pain where the total duration of non-PBS and PBS opioid analgesic treatment
                Morphine                   (i) exceeds 12 months and the palliative care patient is unable to have annual pain management review due to their clinical condition; or
                Oxycodone                  (ii) exceeds 12 months and the patient's clinical need for continuing opioid treatment has been confirmed through consultation with the patient by another medical practitioner or a palliative care nurse practitioner in the past 12 months; or
                Oxycodone with naloxone    (iii) has exceeded 12 months prior to 1 June 2020 and the patient's clinical need for continuing opioid treatment has not been